Shire PLC Company Profile (LON:SHP)

Analyst Ratings

Consensus Ratings for Shire PLC (LON:SHP) (?)
Ratings Breakdown: 1 Sell Rating(s), 1 Hold Rating(s), 18 Buy Rating(s)
Consensus Rating:Buy (Score: 2.85)
Consensus Price Target: GBX 5,731.33

Analysts' Ratings History for Shire PLC (LON:SHP)
Show:
DateFirmActionRatingPrice TargetActions
7/26/2016BNP ParibasReiterated RatingOutperformGBX 5,700View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/22/2016Shore CapitalReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/22/2016Royal Bank Of CanadaReiterated RatingOutperformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/13/2016Citigroup Inc.Reiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/13/2016JPMorgan Chase & Co.Reiterated RatingOverweightGBX 5,600View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/13/2016Deutsche Bank AGReiterated RatingBuyGBX 6,000View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/12/2016Liberum CapitalReiterated RatingBuyGBX 5,500View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/12/2016Goldman Sachs Group Inc.Reiterated RatingBuyGBX 6,300View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/6/2016Berenberg BankReiterated RatingBuyGBX 5,800View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/4/2016Credit Suisse Group AGReiterated RatingOutperformGBX 5,000View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/1/2016HSBCReiterated RatingBuyGBX 5,400View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/6/2016Jefferies GroupBoost Price TargetBuyGBX 5,150 -> GBX 6,050View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/3/2016Morgan StanleyReiterated RatingOverweightGBX 5,600View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/15/2016Sanford C. BernsteinReiterated RatingOutperformGBX 5,000View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/10/2016AlphaValueReiterated RatingBuyGBX 6,420View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/12/2016S&P Equity ResearchReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/5/2016Barclays PLCReiterated RatingOverweightGBX 5,700View Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/3/2015InvestecDowngradeSellView Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/3/2015Kepler Capital MarketsLower Price TargetBuyGBX 6,000 -> GBX 5,900View Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/19/2015Bank of America Corp.Reiterated RatingNeutralGBX 6,000View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/18/2015XYZ ResearchReiterated RatingOutperformGBX 6,600View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/30/2015Charles StanleyReiterated RatingaccumulateView Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/26/2014 forward)

Earnings

Earnings History for Shire PLC (LON:SHP)
No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

Earnings Estimates for Shire PLC (LON:SHP)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Shire PLC (LON:SHP)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable DateShare
2/11/2016GBX 15.320.44%3/10/20163/10/20164/12/2016Tweet This Announcement  Share This Announcement on StockTwits
7/23/2015GBX 2.690.05%9/3/20159/3/201510/2/2015Tweet This Announcement  Share This Announcement on StockTwits
7/18/2014GBX 2.240.04%9/3/20149/3/201410/3/2014Tweet This Announcement  Share This Announcement on StockTwits
2/13/2014GBX 10.210.31%3/5/20143/5/20144/8/2014Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading History for Shire PLC (LON:SHP)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
6/30/2016Bohuon,OlivierInsiderBuy134GBX 4,463£5,980.42Tweet This Trade  Share This Trade on StockTwits
3/31/2016Bohuon,OlivierInsiderBuy133GBX 3,908£5,197.64Tweet This Trade  Share This Trade on StockTwits
2/15/2016Bohuon,OlivierInsiderBuy1,000GBX 3,552£35,520Tweet This Trade  Share This Trade on StockTwits
2/12/2016Burns,WilliamInsiderBuy1,250GBX 3,563£44,537.50Tweet This Trade  Share This Trade on StockTwits
12/18/2015Burns,WilliamInsiderBuy156GBX 4,457£6,952.92Tweet This Trade  Share This Trade on StockTwits
9/30/2015Blakemore ,DominicInsiderBuy129GBX 4,498£5,802.42Tweet This Trade  Share This Trade on StockTwits
6/30/2015Kappler,David JInsiderBuy126GBX 51.05GBX 6,432.30Tweet This Trade  Share This Trade on StockTwits
3/31/2015Susan KilsbyInsiderBuy375GBX 5,327£19,976.25Tweet This Trade  Share This Trade on StockTwits
12/19/2014Steven GillisInsiderBuy228GBX 4,654£10,611.12Tweet This Trade  Share This Trade on StockTwits
10/30/2014Steven GillisInsiderBuy381GBX 4,098£15,613.38Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Shire PLC (LON:SHP)
DateHeadline
07/26/16 04:17 PMHow Much Revenue Growth Will Shire Record in 2Q16? -
07/25/16 06:33 PMONIVYDE® Receives Positive CHMP Opinion for Treatment of Patients with Metastatic Adenocarcinoma of the Pancreas Who Have Pr...
07/25/16 10:50 AMMerrimack: ONIVYDE Regimen Gets Positive CHMP Opinion In EU -Quick Facts
07/25/16 10:50 AMONIVYDE® Receives Positive CHMP Opinion for Treatment of Patients with ...
07/21/16 09:14 AMShire Plc (LON:SHP) Analyst Target Changes - Fiscal Standard
07/20/16 09:18 AMFTSE 100 Index pares gains as pound rises on UK job news
07/19/16 08:36 AMShire Plc (LON:SHP) New Price Targets - FTSE News
07/19/16 06:00 AMShire Reinforces Commitment in Hematology with Robust Data Presented at International Congress of the World Federation of Hemophilia - [PR Newswire] - Shire plc (LSE: SHP, NASDAQ: SHPG), following its combination with Baxalta in June, will affirm its commitment to advancing patient care and scientific innovation at the International Congress of the World Federation of Hemophilia (WFH) in Orlando, Florida, July 24-28, 2016. Data at the Congress this year will showcase the company's robust hematology portfolio and pipeline. Shire is committed to introducing new treatments in hemophilia and other bleeding disorders and aims to enhance patients' experiences with these chronic bleeding disorders.
07/16/16 05:47 PMAre Analysts Bullish Shire PLC (LON:SHP) After Last Week? - Consumer Eagle
07/15/16 11:38 AMShire PLC (LON:SHP) Stock Rating Reiterated at Liberum Capital; The GBX 5500.00 Target Indicates 12.80% Potential - Consumer Eagle
07/15/16 11:38 AMShire PLC (LON:SHP) price target held steady at 5500GBX as issued in a report today by Liberum Capital - Breaking Finance News
07/14/16 06:40 PMShire PLC (LON:SHP) price target held steady at 5,500GBX as issued in a report today by Liberum Capital
07/14/16 10:02 AMA report released today by Deutsche Bank about Shire PLC(LON:SHP) maintains the target price at 6,000GBX
07/13/16 06:48 PMA statement released today by JP Morgan Cazenove about Shire PLC(LON:SHP) holds the target price at 5,600GBX
07/13/16 09:17 AMMultimedia assets now available: FDA Approves Shire's Xiidra™ (lifitegrast ophthalmic solution) 5% - …
07/13/16 09:17 AMLiberum Capital recorded (LON:SHP) Shire PLC, keeping its price target at 5,500GBX earlier today
07/12/16 06:38 PMFDA approves Shire's keenly-watched eye drug
07/12/16 10:47 AMShire’s Xiidra receives FDA approval for treating dry eye disease in adult patients
07/12/16 10:47 AMShire Surges After FDA Approves Xiidra Drops for Dry-Eye Disease
07/12/16 10:47 AMFDA approves Shire’s keenly-watched eye drug
07/12/16 10:47 AMGreen light for Shire dry eye drug adds £1.3bn to co's value
07/12/16 10:47 AMGoldman Sachs issued a report on (LON:SHP) Shire Plc, hiking its target price to 6,300GBX today
07/12/16 10:06 AMDow, S&P 500 hit record highs on greater risk tolerance - [Reuters] - The U.S. S&P 500 and Dow Jones industrial average stock indexes set record intraday highs on Tuesday after reduced global political tensions and upbeat corporate results from Alcoa boosted risk appetite, while European shares also rallied. The benchmark S&P 500 hit 2,151.96, topping Monday's intraday record high by about 8 points, while the Dow rose to 18,353.76 to top its previous record intraday high touched in May 2015. The tech-heavy Nasdaq Composite also gained, wiping out its losses for the year.
07/12/16 10:05 AMGLOBAL MARKETS-Dow, S&P 500 hit record highs on greater risk tolerance - [Reuters - UK Focus] - The U.S. S&P 500 and Dow Jones industrial average stock indexes set record intraday highs on Tuesday after reduced global political tensions and upbeat corporate results from Alcoa (NYSE: AA - news) boosted risk appetite, while European shares also rallied. The benchmark S&P 500 hit 2,151.96, topping Monday's intraday record high by about 8 points, while the Dow rose to 18,353.76 to top its previous record intraday high touched in May 2015. The tech-heavy Nasdaq Composite also gained, wiping out its losses for the year.
07/07/16 01:21 AMShire Receives Extension of Market ... - [at noodls] - July 7, 2016 First therapy indicated in the EU for use in patients aged one year and above with SBS, a rare gastrointestinal condition ZUG, Switzerland - July 7, 2016 - Shire (LSE: SHP, NASDAQ: SHPG) today ...
07/07/16 01:00 AMShire Receives Extension of Market Authorization in Europe for Revestive▼ (Teduglutide) for the Treatment of Paediatric Patients with Short Bowel Syndrome (SBS) - [PR Newswire] - Shire (LSE: SHP, NASDAQ: SHPG) today announced that the European Commission has granted extension of Market Authorization for Revestive®* (teduglutide) 5 mg powder and solvent for solution for injection for the treatment of patients aged one year and above with Short Bowel Syndrome (SBS). SBS is a rare gastrointestinal condition characterised by a clinically significant reduction in intestinal absorptive capacity as a consequence of surgical resection of large portions of the intestine, commonly due to congenital abnormalities, disease or trauma. The European Commission decision to grant extension of Market Authorization for Revestive in the treatment of paediatric patients with SBS follows a positive opinion adopted by the Committee for Medicinal Products for Human Use (CHMP) in May 2016.
07/05/16 10:49 AMDeutsche Bank recorded (LON:SHP) Shire PLC, boosting its price target to GBX6,000 today
07/04/16 10:56 AMShire Plc (LON:SHP) price target bumped up to GBX5,000, reported today by Credit Suisse
07/03/16 10:31 AMShire PLC (LON:SHP) target price maintained to GBX5,600 as reported today by Deutsche Bank
07/02/16 05:55 PMExane BNP Paribas Reiterated Shire PLC (LON:SHP) As 'Outperform' - FTSE News
07/01/16 06:24 PMShire PLC (LON:SHP) Receives Outperform Rating From Exane BNP Paribas Analysts - Fiscal Standard
07/01/16 09:06 AMShire Persists With Drug for Premature Babies After Study Fails
07/01/16 09:06 AMShire PLC (LON:SHP) price target held steady to GBX5,700, reported today by Exane BNP Paribas
06/30/16 09:10 AMBrexit could send share prices soaring at ARM Holdings plc, Shire plc and Imperial Brands plc
06/30/16 09:10 AMShire: SHP607 Trial Shows Positive Secondary Endpoints Related To Lung, Brain
06/29/16 06:18 PMShire : Reports Encouraging Results for ADHD Drug
06/27/16 06:19 PMShares Of Shire Plc (LON:SHP) Rated As Outperform By Analysts At Exane BNP Paribas - Fiscal Standard
06/18/16 05:31 PMDeutsche Bank disclosed (LON:SHP) Shire PLC, keeping its stock price target to GBX5,600 today - Breaking Finance News
06/18/16 10:27 AMDeutsche Bank disclosed (LON:SHP) Shire PLC, keeping its stock price target to GBX5,600 today
06/16/16 06:36 PMRBC Capital Markets reported on (LON:SHP) Shire PLC, maintaining its target price to GBX0 earlier today
06/16/16 10:47 AMRBC Capital Markets reported on (LON:SHP) Shire PLC, maintaining its target price to GBX0 earlier today - Breaking Finance News
06/15/16 10:52 AMShire, Kamada: FDA Approves Expanded Label For Self-infusion Of GLASSIA
06/14/16 11:09 AMSHIRE PLC : - Additional Listing
06/14/16 11:09 AMShire To License IBD Drug PF-00547659 From Pfizer; Terms Not Disclosed
06/14/16 11:09 AMCompany Update (NYSE:PFE): Shire to License PF-00547659 from Pfizer, Adding to Established and Leading Gastrointestinal Portfolio
06/13/16 09:21 AMShire : Gets Breakthrough Therapy Designation For SHP621 And SHP625
06/13/16 09:21 AMShire Gets FDA Breakthrough Therapy Designation For 2 Products For Rare Diseases
06/13/16 09:21 AMShire Receives FDA Breakthrough Therapy Designation for SHP621 and SHP625, Investigational Products for Rare Gastrointestinal Conditions
06/10/16 09:23 AMJefferies International Reiterated Shire PLC (LON:SHP) As 'Buy' - FTSE News
06/09/16 12:30 PMETF’s with exposure to Shire Plc : June 9, 2016 -

Social

About Shire PLC

Shire PLC logoShire plc is a biotech company. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other select conditions. The Company operates in the segment of research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. The Company focuses its development resources on projects in various therapeutic areas (TAs), including rare diseases, neuroscience, ophthalmics, hematology and gastrointestinal (GI), and focuses its early development projects primarily on rare diseases. Its products include VYVANSE/VENVANSE/ELVANSE/TYVENSE/ELVANSE VUXEN/ADUVANZ, ADDERALL XR, INTUNIV, LIALDA (mesalamine)/MEZAVANT(mesalazine), PENTASA (mesalamine), REPLAGAL (agalsidase alfa), ELAPRASE (idursulfase), VPRIV (velaglucerase alfa), FIRAZYR (icatibant), CINRYZE C1 esterase inhibitor (human), GATTEX/REVESTIVE, NATPARA/NATPAR, FOSRENOL (lanthanum carbonate) and KALBITOR.

Industry, Sector and Symbol:
  • Sector: N/A
  • Industry: N/A
  • Sub-Industry: N/A
  • Exchange: LON
  • Symbol: SHP
  • CUSIP:
Key Metrics:
  • Previous Close: $65.07
  • 50 Day Moving Average: $4500.76
  • 200 Day Moving Average: $4148.47
  • P/E Ratio: 22.12
  • P/E Growth: 1.01
  • Market Cap: $29.03B
  • Current Year EPS Consensus Estimate: $4.24 EPS
  • Next Year EPS Consensus Estimate: $N/A EPS
Additional Links: